Abstract: An infusion system may include a strontium-rubidium radioisotope generator that generates a radioactive eluate via elution, a beta detector, a gamma detector, and a controller. The beta detector and the gamma detector may be positioned to measure beta emissions and gamma emissions, respectively, emitted from the radioactive eluate. In some examples, the controller is configured to determine an activity of rubidium in the radioactive eluate based on the beta emissions measured by the beta detector and determine an activity of strontium in the radioactive eluate based on the gamma emissions measured by the gamma detector.

Abstract: An infusion system (10) including a radioisotope generator (52) that generates a radioactive eluate via an elution, an activity detector (58) configured to measure an activity of a first radioisotope in the radioactive eluate generated by the radioisotope generator, and a controller (80). The controller can track a cumulative volume of radioactive eluate generated by the radioisotope generator and also track the activity of the first radioisotope in the radioactive eluate generated by the radioisotope generator. The controller can determine a predicted volume of the radioactive eluate generated by the radioisotope generator at which the activity of the first radioisotope in the radioactive eluate will reach a threshold based on the tracked cumulative volume of the radioactive eluate and the tracked activity of the first radioisotope. This information can be useful for proactively removing the radioisotope generator from service and/or replacing the radioisotope generator with a fresh generator.

Abstract: A nuclear medicine infusion system (10) may be used to generate and infuse radioactive liquid into a patient undergoing a diagnostic imaging procedure. In some examples, the infusion system includes a frame (30) that carries a radioisotope generator (52) that generates radioactive eluate via elution. The frame may also carry a beta detector (58) and a gamma detector (60). The beta detector can be positioned to measure beta emissions emitted from the radioactive eluate supplied by the generator. The gamma detector can be positioned to measure gamma emissions emitted from a portion of the radioactive eluate to evaluate a safety of the radioactive eluate delivered by the infusion system.

Abstract: An infusion system can include a radioisotope generator that generates a radioactive eluate via an elution, an activity detector configured to measure an activity of the radioactive eluate generated by the radioisotope generator, and a controller. The controller can analyze a radioactivity profile of the radioactive eluate to determine a characteristic of the profile indicative of breakthrough. The controller may issue a user alert, cease elution, or perform yet other actions based on the analysis.

Abstract: An infusion system (10) including a radioisotope generator (52) that generates a radioactive eluate via an elution, an activity detector (58) configured to measure an activity of a first radioisotope in the radioactive eluate generated by the radioisotope generator, and a controller (80). The controller can track a cumulative volume of radioactive eluate generated by the radioisotope generator and also track the activity of the first radioisotope in the radioactive eluate generated by the radioisotope generator. The controller can determine a predicted volume of the radioactive eluate generated by the radioisotope generator at which the activity of the first radioisotope in the radioactive eluate will reach a threshold based on the tracked cumulative volume of the radioactive eluate and the tracked activity of the first radioisotope. This information can be useful for proactively removing the radioisotope generator from service and/or replacing the radioisotope generator with a fresh generator.

Abstract: An infusion system may include a radioisotope generator that generates a radioactive eluate via elution, a beta detector, a gamma detector, and a controller. The beta detector and the gamma detector may be positioned to measure beta emissions and gamma emissions, respectively, emitted from the radioactive eluate. In some examples, the controller is configured to calibrate the infusion system using the gamma detector. For example, the controller may generate a radioactive eluate and measure the activity of the radioactive eluate using both the beta detector and the gamma detector. The high accuracy of the activity measured by the gamma detector may be used to calibrate the infusion system. In subsequent use, the infusion system calibrated using the gamma detector may adjust measurements made to monitor and/or control patient infusion procedures.

Abstract: A shielding assembly may be used in a nuclear medicine infusion system that generates and infuse radioactive liquid into a patient undergoing a diagnostic imaging procedure. In some examples, the shielding assembly has multiple compartments each formed of a shielding material providing a barrier to radioactive radiation. For example, the shielding assembly may have a first compartment configured to receive a radioisotope generator that generates a radioactive eluate via elution, a second compartment configured to receive a beta detector, and a third compartment configured to receive a gamma detector. In some examples, the compartments are arranged to minimize background radiation emitted by the radioisotope generator and detected by the gamma detector to enhance the quality of the measurements made by the gamma detector.

Abstract: An infusion system may include a strontium-rubidium radioisotope generator that generates a radioactive eluate via elution, a beta detector, a gamma detector, and a controller. The beta detector and the gamma detector may be positioned to measure beta emissions and gamma emissions, respectively, emitted from the radioactive eluate. In some examples, the controller is configured to determine an activity of rubidium in the radioactive eluate based on the beta emissions measured by the beta detector and determine an activity of strontium in the radioactive eluate based on the gamma emissions measured by the gamma detector.

Abstract: A nuclear medicine infusion system (10) may be used to generate and infuse radioactive liquid into a patient undergoing a diagnostic imaging procedure. In some examples, the infusion system includes a frame (30) that carries a radioisotope generator (52) that generates radioactive eluate via elution. The frame may also carry a beta detector (58) and a gamma detector (60). The beta detector can be positioned to measure beta emissions emitted from the radioactive eluate supplied by the generator. The gamma detector can be positioned to measure gamma emissions emitted from a portion of the radioactive eluate to evaluate a safety of the radioactive eluate delivered by the infusion system.

Abstract: A shielding assembly may be used in a nuclear medicine infusion system that generates and infuse radioactive liquid into a patient undergoing a diagnostic imaging procedure. In some examples, the shielding assembly has multiple compartments each formed of a shielding material providing a barrier to radioactive radiation. For example, the shielding assembly may have a first compartment configured to receive a radioisotope generator that generates a radioactive eluate via elution, a second compartment configured to receive a beta detector, and a third compartment configured to receive a gamma detector. In some examples, the compartments are arranged to minimize background radiation emitted by the radioisotope generator and detected by the gamma detector to enhance the quality of the measurements made by the gamma detector.

Abstract: The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 ?M), and dimer and multimeric constructs comprising these polypeptides.

Abstract: New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure: wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

Abstract: The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, compositions containing the same and methods for their use. Additionally, the present invention includes diagnostic, therapeutic and radiotherapeutic compositions useful for visualization, therapy or radiotherapy.

Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.

Abstract: New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure: wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

Abstract: Stabilized radiopharmaceutical formulations are disclosed. Methods of making and using stabilized radiopharmaceutical formulations are also disclosed. The invention relates to stabilizers that improve the radiostability of radiotherapeutic and radiodiagnostic compounds, and formulations containing them. In particular, it relates to stabilizers useful in the preparation and stabilization of targeted radiodiagnostic and radiotherapeutic compounds, and, in a preferred embodiment, to the preparation and stabilization of radiodiagnostic and radiotherapeutic compounds that are targeted to the Gastrin Releasing Peptide Receptor (GRP-Receptor).

Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.

Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.

Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.

Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.